MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse
Latest Information Update: 08 Nov 2024
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PEMAZA
Most Recent Events
- 06 Nov 2024 Planned End Date changed from 1 Aug 2024 to 1 Dec 2026.
- 06 Nov 2024 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2025.
- 11 Mar 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2024.